Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Olaparib
Sponsor: Monica Mita
Collaborators: Merck Sharp & Dohme LLC